미국의 심혈관 기기 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 제품별, 최종 용도별, 부문별 예측(2025-2033년)

U.S. Cardiovascular Devices Market Summary

The U.S. cardiovascular devices market size was estimated at USD 22.39 billion in 2024 and is projected to reach USD 37.66 billion by 2033, growing at a CAGR of 5.8% from 2025 to 2033. A cardiovascular device is a medical tool explicitly used to diagnose or treat diseases of the heart and blood vessels, including instruments like pacemakers, stents, artificial valves, defibrillators, angioplasty tools, and cardiac catheters.

The rising incidence of cardiovascular diseases is one of the factors boosting market growth. According to the America Heart Association (AHA), in January 2024, there were 931,578 deaths in the U.S. attributed to cardiovascular disease, marking an increase of nearly 3,000 compared to the previous year. Additionally, the age-adjusted death rate from cardiovascular conditions rose to 233.3 per 100,000 individuals, reflecting a 4.0% increase from the prior year. This upward trend in mortality rates emphasizes the ongoing challenges posed by cardiovascular diseases, highlighting the critical need for innovative cardiovascular devices and interventions.

Moreover, as per the American Heart Association (AHA) article published in June 2024, cardiovascular disease (CVD) could affect over 184 million Americans, more than 61% of the population, by 2050. Alongside this expected rise in prevalence, CVD-related healthcare costs are expected to escalate dramatically, potentially reaching USD 1.8 trillion. This forecasted growth in cases and associated costs highlights an urgent need for advancements in cardiovascular devices. Therefore, the U.S. cardiovascular devices market is positioned for substantial growth as demand intensifies for innovative technologies that support early diagnosis, preventive care, and effective treatment solutions to manage the widespread impact of CVD on public health.

Increasing awareness campaigns and government-initiated screening programs for early detection of CVDs contribute to market expansion by ensuring more patients receive timely diagnosis and treatment. According to the American Heart Association, Inc. article published in November 2023, the 2023 guidelines from the American Heart Association (AHA), American College of Cardiology (ACC), American College of Chest Physicians (ACCP), and the Heart Rhythm Society (HRS) for the diagnosis & management of AFib stress the importance of raising awareness and implementing routine screening, especially in high-risk groups like older adults. These guidelines advocate for regular pulse and ECG screenings to ensure early detection and effective management of CVDs. For instance, early identification and treatment of AFib are crucial as they can significantly lower the risk of stroke and other serious complications.

The efficiency of targeted screening programs for CVDs fuels market growth. According to Springer Nature, in June 2024, a review of cardiology reports will examine the impact of screening programs. It highlights findings from multicenter studies, such as STROKESTOP and AF-SCREEN, which show that targeted screening greatly enhances the detection of CVDs, especially among older adults. The review strongly supports establishing national screening initiatives to address the growing burden of AFib-related complications, highlighting the critical role of early detection and intervention.

U.S. Cardiovascular Devices Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. cardiovascular devices market report based on product, and end-use:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Diagnostic & Monitoring
  • ECG
  • Implantable Cardiac Monitors
  • Holter Monitors
  • Mobile Cardiac Telemetry
  • MRI
  • Cardiovascular Ultrasound
  • Cardiac Diagnostic Catheters
  • PET Scanner
• Surgical Devices
  • Cardiac Resynchronization Therapy (CRT)
  • Implantable Cardioverter Defibrillators (ICDs)
  • Pacemakers
  • Coronary Stents
  • Catheters
  • Guidewires
  • Cannula
  • Valves
  • Occlusion Devices
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Ambulatory Surgical Centers
• Diagnostic Centers
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecast timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity price analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product Segment
  • 2.2.2. End Use Segment
  • 2.2.3. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Cardiovascular Devices Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of cardiovascular diseases (CVDs)
    • 3.2.1.2. Increasing awareness and screening programs
    • 3.2.1.3. Technological advancement in CVDs devices
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High costs associated with the devices
    • 3.2.2.2. Product Recalls
• 3.3. U.S. Cardiovascular Devices Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. U.S. Cardiovascular Devices Market: Product Estimates & Trend Analysis

• 4.1. U.S. Cardiovascular Devices Market: Product Dashboard
• 4.2. U.S. Cardiovascular Devices Market: Product Movement Analysis
• 4.3. U.S. Cardiovascular Devices Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Diagnostic & Monitoring
  • 4.4.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.4.2. ECG
    • 4.4.2.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.4.3. Implantable Cardiac Monitors
    • 4.4.3.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.4.4. Holter Monitors
    • 4.4.4.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.4.5. Mobile Cardiac Telemetry
    • 4.4.5.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.4.6. MRI
    • 4.4.6.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.4.7. Cardiovascular Ultrasound
    • 4.4.7.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.4.8. Cardiac Diagnostic Catheters
    • 4.4.8.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.4.9. PET Scanner
    • 4.4.9.1. Market estimates and forecast 2021 - 2033 (USD Million)
• 4.5. Surgical Devices
  • 4.5.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.5.2. Cardiac Resynchronization Therapy (CRT)
    • 4.5.2.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.5.3. Implantable Cardioverter Defibrillators (ICDs)
    • 4.5.3.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.5.4. Pacemakers
    • 4.5.4.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.5.5. Coronary Stents
    • 4.5.5.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.5.6. Catheters
    • 4.5.6.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.5.7. Guidewires
    • 4.5.7.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.5.8. Cannula
    • 4.5.8.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.5.9. Valves
    • 4.5.9.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.5.10. Occlusion Devices
    • 4.5.10.1. Market estimates and forecast 2021 - 2033 (USD Million)

Chapter 5. U.S. Cardiovascular Devices Market: End Use Estimates & Trend Analysis

• 5.1. U.S. Cardiovascular Devices Market: End Use Dashboard
• 5.2. U.S. Cardiovascular Devices Market: End Use Movement Analysis
• 5.3. U.S. Cardiovascular Devices Market Size & Forecasts and Trend Analysis, by End Use , 2021-2033 (USD Million)
• 5.4. Hospitals
  • 5.4.1. Market estimates and forecast 2021 - 2033 (USD Million)
• 5.5. Ambulatory Surgical Centers
  • 5.5.1. Market estimates and forecast 2021 - 2033 (USD Million)
• 5.6. Diagnostic Centers
  • 5.6.1. Market estimates and forecast 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Market estimates and forecast 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Recent Developments & Impact Analysis, By Key Manufacturers
• 6.2. Company/Competition Categorization
• 6.3. Vendor Landscape
  • 6.3.1. List of key distributors and channel partners
  • 6.3.2. Key customers
  • 6.3.3. Key company market share analysis, 2024
  • 6.3.4. Abbott
    • 6.3.4.1. Company overview
    • 6.3.4.2. Financial performance
    • 6.3.4.3. Product benchmarking
    • 6.3.4.4. Strategic initiatives
  • 6.3.5. GE HealthCare
    • 6.3.5.1. Company overview
    • 6.3.5.2. Financial performance
    • 6.3.5.3. Product benchmarking
    • 6.3.5.4. Strategic initiatives
  • 6.3.6. Edwards Lifesciences Corporation
    • 6.3.6.1. Company overview
    • 6.3.6.2. Financial performance
    • 6.3.6.3. Product benchmarking
    • 6.3.6.4. Strategic initiatives
  • 6.3.7. Siemens Healthineers AG
    • 6.3.7.1. Company overview
    • 6.3.7.2. Financial performance
    • 6.3.7.3. Product benchmarking
    • 6.3.7.4. Strategic initiatives
  • 6.3.8. Canon Medical Systems
    • 6.3.8.1. Company overview
    • 6.3.8.2. Financial performance
    • 6.3.8.3. Product benchmarking
    • 6.3.8.4. Strategic initiatives
  • 6.3.9. B. Braun SE
    • 6.3.9.1. Company overview
    • 6.3.9.2. Financial performance
    • 6.3.9.3. Product benchmarking
    • 6.3.9.4. Strategic initiatives
  • 6.3.10. LivaNova, Inc.
    • 6.3.10.1. Company overview
    • 6.3.10.2. Financial performance
    • 6.3.10.3. Product benchmarking
    • 6.3.10.4. Strategic initiatives
  • 6.3.11. Cardinal Health
    • 6.3.11.1. Company overview
    • 6.3.11.2. Financial performance
    • 6.3.11.3. Product benchmarking
    • 6.3.11.4. Strategic initiatives
  • 6.3.12. Medtronic
    • 6.3.12.1. Company overview
    • 6.3.12.2. Financial performance
    • 6.3.12.3. Product benchmarking
    • 6.3.12.4. Strategic initiatives
  • 6.3.13. Boston Scientific Corporation
    • 6.3.13.1. Company overview
    • 6.3.13.2. Financial performance
    • 6.3.13.3. Product benchmarking
    • 6.3.13.4. Strategic initiatives
  • 6.3.14. W. L. Gore & Associates, Inc.
    • 6.3.14.1. Company overview
    • 6.3.14.2. Financial performance
    • 6.3.14.3. Product benchmarking
    • 6.3.14.4. Strategic initiatives
  • 6.3.15. BIOTRONIK SE & Co. KG
    • 6.3.15.1. Company overview
    • 6.3.15.2. Financial performance
    • 6.3.15.3. Product benchmarking
    • 6.3.15.4. Strategic initiatives